Introduction
============

Although the theory of cancer stem cells dates back more than 50 years, the existence of the first *bona fide*tumorigenic cell compartment was not demonstrated until 1994, when the acute myelogenous leukemia stem cell (LSC) was identified and characterized \[[@B1]\]. Since then, despite accumulating evidence that LSCs are responsible for maintenance and transfer of blood cancers, researchers doubted the existence of an analogous cell type in solid tumors. In fact, it was believed that every cell from a tumor had an equal likelihood of seeding a secondary cancer as long as it was in the correct microenvironment. However, in 2003 an influential report describing the prospective identification of human breast cancer stem cells changed the landscape of breast cancer research \[[@B2]\]. Using various human tumor samples (eight pleural effusions and one primary tumor), which were xenografted into the mammary glands of nonobese diabetic/severe combined immunodeficient mice, the investigators reported that a small population of CD44^+^/CD24^-^/Lin^-^human breast cancer cells were enriched for tumorigenic potential.

Most researches now consider that, like leukemia, solid tumors such as prostate, breast, colon, brain, and pancreatic cancers contain a small fraction of self-renewing tumorigenic cells that give rise to and maintain the bulk of the tumor mass. The use of Hoescht dye efflux, suspension sphere assays, and serial transplantation are all proposed methods for identifying and separating cancer stem cells from solid tumors. However, arguably the most effective method of identifying these cells, which may be morphologically indistinct from the bulk of the cancer, is through differential cell surface protein expression.

The choice and relevance of solid tumor markers
===============================================

The relevance of current cancer stem cell markers for solid tumors remains controversial and perplexing. In leukemia, the rationale for using the cell surface makers CD34^+^/CD38^-^to identify LSCs was based on the known and shared markers for hematopoietic stem cells. However, in the case of breast cancer, the rationale for selection of prospective markers is less clear, primarily because the human breast stem cell has not yet been extensively characterized. Although a putative murine mammary stem cell was recently reported \[[@B3],[@B4]\], the markers used in these studies have yet to be applied to human breast cancer stem cells. More importantly, even if researchers do apply the mouse markers to human cells, lessons learned from the hematopoietic field would suggest that the markers in mouse may not translate to humans (for instance, CD38 and Sca1).

For solid tumors, the repertoire of cell surface markers currently used to identify human cancer stem cells includes CD44, CD133, epithelial surface antigen (ESA), and CD24, either singly or in combination. Specifically, the CD44^+^phenotype is correlated positively with colon, breast, prostate, and pancreatic cancer initiator cells \[[@B2],[@B5]-[@B7]\]. Likewise, CD133^+^cells have been shown to initiate human glioblastoma, colon, prostate, and pancreatic cancers in mice \[[@B5]-[@B8]\]. The phenotype of pancreatic and breast cancer initiator cells and normal breast progenitor cells is ESA^+^\[[@B2],[@B7],[@B9]\]. Finally, CD24 has a more ambiguous past because it is positively correlated with tumorigenicity in pancreatic cancer \[[@B7]\] but negatively correlated in breast cancer \[[@B2]\], yet CD24^+^cells are associated with invasive breast cancer \[[@B10]\].

The functional significance of these proteins is an area of investigation that remains poorly understood. It has been suggested that CD44 is an important molecule for metastasis because a nonmetastatic rat glioma cell line acquired metastatic properties when a splice variant of CD44 was ectopically over-expressed \[[@B11]\]. In addition, CD44 variant isoforms are differentially expressed during pregnancy and involution, indicating a role in normal breast epithelial homeostasis \[[@B12]\]. ESA is another molecule that deserves further investigation because it was shown to be essential for migration and invasion of the human breast cancer cell line MDA.MB.231 \[[@B13]\].

Regardless of the biologic activities of these markers, it is remarkable that the same cell surface markers enrich for tumor stem cells across many solid tumor types. Therefore, perhaps the markers that are currently used to identify \'stem cells\' from solid tumors could actually be enriching for cells with certain functional properties *in vivo*or *in vitro*, namely to engraft successfully in mouse or to adhere and expand in culture. This theory is supported by the fact that nearly all studies on the prospective identification of human solid tumor stem cells have either xenografted the primary tumor into a nonobese diabetic/severe combined immunodeficient mouse, or briefly conditioned the tumor cells in culture before enriching for tumor initiating cells \[[@B2],[@B5]-[@B7]\].

What defines a cancer stem cell?
================================

The definition of a stem cell is the ability to self-renew and give rise to a daughter cell that is different from itself. The \'gold standard\' in demonstrating stem cell activity is the ability to reconstitute a diverse tissue *in vivo*(normal or malignant). Although this is straightforward when studying murine stem cells, because the mouse serves as the natural host for engraftment studies, it is more complex when the only means for defining a human cancer stem cell is its ability to engraft in a mouse. Thus, if a cancer cell cannot successfully engraft into a mouse because of a species, hormonal, or micro-environment incompatibility, does this mean that the cell is not a cancer stem cell?

The importance of microenvironment was recently illustrated in an elegant study with leukemia \[[@B14]\]. In this study, murine LSCs deficient for CD44 introduced into the circulation of mice were unable to home to the bone marrow and thus could not form leukemia. However, the same CD44-deficient LSCs injected directly into the bone marrow were fully able to engraft and regenerate a heterogeneous tumor. Based on this work, it is clear that cancer stem cells that give rise to a heterogeneous tumor can exist, but if that same cell cannot engraft because of an incompatible microenvironment, should it no longer be defined as a cancer stem cell?

For human breast cancers, is it the case that CD44^+^/CD24^-^cells are simply better at engrafting in the mouse mammary microenvironment, or are they really more tumorigenic in the human setting? The murine mammary gland is an excellent site for transplantation of primary mouse mammary epithelial cells (normal and neoplastic) because it is the natural stromal microenvironment for murine mammary cells. However, attempts to introduce human mammary epithelial cells (normal or malignant) into mouse mammary fat pads were only successful when the fibrous stroma of the human breast was recreated \[[@B15]-[@B17]\]. Because the stromal cells that are adjacent to cancer cells can facilitate their engraftment and tumor formation \[[@B16],[@B18],[@B19]\], it is plausible that CD44^+^/CD24^-^breast cancer cells are merely the cells that are the most successful in overcoming an engraftment incompatibility that exists when injecting human cells into the mouse adipose stroma.

The relevance of CD44 and CD24 in human breast cancer
=====================================================

Several studies that have attempted to repeat and expand on the CD44^+^/CD24^-^breast cancer initiator cell profile have thus far been inconclusive. In 2004, a clinical study reported that there was no statistically significant CD44 or CD24 staining in primary breast cancer sections in relation to tumor grade, type, or size \[[@B20]\]. The authors postulated that one difference is that they use primary sections, in which a pathologist can identify tumor tissue, whereas in their study Al-Hajj and coworkers \[[@B2]\] used cell sorting to remove Lin^-^cells and subsequent flow cytometry. However, two more recent reports \[[@B21],[@B22]\] have now confirmed, both in breast cancer derived cell lines and breast tumors, that CD44^+^/CD24^-^phenotypes are not necessarily associated with patient outcome or ability to metastasize.

In recent work, Shipitsin and coworkers \[[@B22]\] found that CD24 is expressed on more differentiated cells whereas CD44 is expressed on more progenitor-like cells. Specifically, they found that breast cells of the CD44^+^/CD24^-^phenotype express genes that are involved in cell motility and angiogenesis, are more mesenchymal, are motile, and are predominately estrogen receptor negative. In agreement with this study, we and others have also observed a strong association between breast cancer cells with a basal-like or mesenchymal-like phenotype (MDA.MB.231, SUM159, SUM1315) and the presence CD44^+^/CD24^-^cells (unpublished data, \[[@B21]\]). In contrast, cells with a more luminal, epithelial appearance (MCF7 and SUM225) were largely CD44^-^/CD24^+^, which is consistent with the luminal differentiated mucin-1-positive, estrogen receptor/progesterone receptor-positive, Gata3-positive cells reported by Shipitsin and coworkers. Taken together, these studies suggest another interesting interpretation of CD24 and CD44 as markers of breast cancer cells; perhaps CD44^+^cells are predominately basal-like and therefore are present in poor prognosis basal-like tumors, whereas CD24^+^cells are luminal-like and therefore present in more differentiated luminal-type cancers.

Conclusion
==========

With the aim being to eradicate breast cancer, there is great interest and excitement in the possibility of identifying and treating the subpopulation of cancer stem cells that fuel tumor growth. However, there remains a need to determine whether CD44^+^/CD24^-^cells are true tumorigenic cells across all the various breast cancer subtypes, or whether these are unique to a more basal tumor type. Fortunately, the field is growing with the identification of new potential markers, such as protein C receptor \[[@B20]\], which may permit further enrichment and identification of therapeutic targets for treatment of breast cancer.
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